Sosudi2
Efficacy and Safety Comparison of the Open (Femoral-popliteal Proximal Bypass) and Endovascular (Recanalization With Angioplasty and Stenting With Biomimetic Interwoven Nitinol Stent) Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04588571/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 110 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2023) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 8
Критерии включения
- age> 18 years;
- Symptomatic lesion (Rutherford category 3 - 6);
- Atherosclerotic prolonged occlusive lesion of the femoropopliteal arterial segment above the knee, classified by TASC II as type D, confirmed by computed tomography or arteriography;
- De novo lesion;
- Patient informed consent.
Критерии невключения
- Age < 18 years old;
- Potentially pregnant women;
- Asymptomatic lesion;
- Acute ischemia;
- Not de novo lesion;
- Severe comorbidity with a life expectancy of fewer than 2 years;
- Contraindications to antiplatelet therapy (double antiplatelet therapy is required for at least 2 months after the intervention);
- Patient participation in another clinical trial;
Источник: ClinicalTrials.gov, NCT04588571 · запись обновлена в реестре 19 октября 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 4
- primary patency — 24 months
- primary assisted patency — 24 months
- secondary patency — 24 months
Цель исследования
Endovascular revascularization and open bypass grafting above the knee show comparable results in primary 2-year patency (about 65%) in medium-length lesions - TASC II, C (Pereira et al, 2006). At the same time, a recent study, where the authors studied the effectiveness of stenting of long lesions (200 mm or more) of the chronic occlusions of the femoropopliteal segments (TASC II, D), showed unsatisfactory results (primary patency 45%) of the stented segment within 2 years (Lin et al, 2015). One of the possible solutions to the problem of breakage of stents in the femoral-popliteal position is a modified method of their manufacture by braiding from nitinol wire. Some studies with intervowen nitinol stents did show their resistance to breakage in this position. Moreover, the primary patency was \> 70%. (Werner et al, 2014). These data suggest a better primary patency rate within 2 years with a longer lesion length (\>200 mm).
This is a prospective, randomized, open-label study. The main objective of the study is to compare the clinical efficacy and safety of two therapies for the treatment of prolonged atherosclerotic lesions of the arteries of the femoropopliteal segment above the knee, TASC II type D - femoropopliteal proximal shunting and recanalization with angioplasty and stenting using biomimetic interwoven nitinol stent in patients with symptomatic peripheral arterial disease at 24 months. Secondary objectives are to identify predictors of restenosis and occlusions of the operating segment and compare the quality of life of patients after the procedure. It is planned to recruit 110 patients (55 patients in each group). Observation period 2 years. Primary endpoint:
-The effectiveness of the method of surgical treatment after 24 months (primary patency, primary-assisted patency, secondary patency).
Secondary endpoints:
* Clinical efficacy of the method of surgical treatment after 24 months (MALE);
* Safety of the method of surgical treatment in the early postoperative period (hematoma of the surgical access area, peripheral neuropathy, purulent-infectious complications of the surgical access area) and after 24 months (MACE);
* Assessment of the quality of life in patients after surgical treatment at 6, 12, and 24 months (SF-36 questionnaire);
* Evaluation of prognostic factors for adverse outcomes after surgical treatment.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04588571 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.